Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor therapy has failed (D2EFT): an open-label, randomised, phase 3b/4 trial,The Lancet HIV

当前位置： X-MOL 学术 › Lancet HIV › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor therapy has failed (D2EFT): an open-label, randomised, phase 3b/4 trial
The Lancet HIV ( IF 12.8 ) Pub Date : 2024-05-21 , DOI: 10.1016/s2352-3018(24)00089-4
Gail Matthews , Simone Jacoby , Margaret Borok , Nnakelu Eriobu , Richard Kaplan , Nagalingeswaran Kumarasamy , Jaclyn Ann Bennet , Anchalee Avihingsanon , Ploenchan Chetchotisakd , Sandra Wagner Cardoso , Iskandar Azwa , Marcelo Losso , Dannae Brown , Dona Arlinda , Jolie Hutchinson , Anthony Kelleher , Mohamed Cisse , Sounkalo Dao , Mark Polizzotto , Sean Emery , Matthew Law , Emmanuelle Papot , Muhammad Karyana , Sergio Lupo , Ana Melisa Solari , Beatriz Grinsztejn , Marcello Wolff , Jaime Andrade-Villanueva , Juan Luis Mosqueda Gómez , Ting Soo Chow , Lerato Mohapi , Evy Yunihastuti , Usman Hadi , Sudirman Katu , Yanri Wijayanti Subronto , H. Clifford Lane , Leonardo Perelis

中文翻译：